ALTME NL0015000YE1

Report

Real-time Euronext Paris - 04:04:45 2023-03-31 am EDT
1.019	EUR		+2.70%

03/27	Tme Pharma N : Inside Information / Other news releases	PU
03/27	TME Pharma N.V. Announces a Clinical Update on Survival of Newly Diagnosed Glioblastoma Patients in the GLORIA Expansion Arm Evaluating NOX-A12, TME Pharma’s CXCL12 Inhibitor	CI
02/24	Tme Pharma N : CEO message	PU

News

Most relevant

Official Publications

Sector news

Most relevant news about TME PHARMA N.V.

03/27	Tme Pharma N : Inside Information / Other news releases	PU
03/27	TME Pharma N.V. Announces a Clinical Update on Survival of Newly Diagnosed Glioblastoma..	CI
02/24	Tme Pharma N : CEO message	PU
01/23	Tme Pharma Provides Clinical Update on the Gloria Expansion Arm Testing Nox-A12 in Comb..	CI
01/20	Tme Pharma N : Half-yearly report on the liquidity contract with Invest Securities	PU
2022	Tme Pharma N : announces convocation of an extraordinary general meeting of shareholders	PU
2022	Biotech Group TMA Pharma's CFO to Leave by 2022-end	MT
2022	Tme Pharma N : announces the resignation of its Chief Financial Officer Bryan Jennings	PU
2022	TME Pharma N.V. Announces the Resignation of Bryan Jennings as Chief Financial Officer	CI
2022	TME Pharma N.V. Announces Executive Changes	CI
2022	Tme Pharma N : The presentation	PU
2022	TME Pharma N.V. - POSITIVE UPDATED INTERIM RESULTS FROM NOX-A12 GLORIA PHASE 1/2 IN BRA..	AQ
2022	TME Pharma Announces Positive Updated Interim Results from NOX-A12 GLORIA Phase 1/2 in ..	CI
2022	Tme pharma announces publication of abstract disclosing positive interim results from b..	AQ
2022	Tme Pharma N : to host key opinion leader webinar	PU
2022	Tme Pharma N : announces publication of abstract disclosing positive interim results from ..	PU
2022	TME Pharma Announces Publication of Abstract Disclosing Positive Interim Results from B..	CI
2022	TME Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
2022	Tme Pharma N : Inside Information / News release on accounts, results	PU
2022	Tme Pharma N : 2022, Half-Year Financial Report as of 30 June 2022	PU
2022	Tme pharma announces upcoming presentation at the society for neuro-oncology annual mee..	AQ
2022	TME Pharma - SAFETY CONFIRMED OF NOX-A12 AND PEMBROLIZUMAB COMBINATION IN GLORIA PHASE ..	AQ
2022	Data Safety Monitoring Board Validates Safety Data for TME Pharma's Brain Cancer Therap..	MT
2022	TME Pharma N.V. Announces Data Safety Monitoring Board Validated Safety Data from the I..	CI
2022	TME Pharma Treats First Brain Cancer Patient In Phase 1/2 Clinical Study	MT
2022	TME Pharma Announces Enrollment of First Patient in Pembrolizumab Expansion Arm of NOX-..	CI
2022	Noxxon Pharma N : Inside Information / Other news releases	PU
2022	French Drugmaker Noxxon Changes Name to TME Pharma	MT
2022	Noxxon pharma announces changes to its supervisory board	AQ
2022	Noxxon pharma - half-yearly report on the liquidity contract with invest securities	AQ
2022	NOXXON Pharma N.V. Announces Resignation of Gregory Weaver from its Supervisory Board, ..	CI
2022	Noxxon Pharma N : Bryan Jennings	PU
2022	Noxxon Pharma N : 1 July 2022	PU
2022	Noxxon Pharma N : AFM notification form MAR 19 – managers transactions	PU
2022	Noxxon provides results of its 2022 annual general meeting of shareholders	AQ
2022	Noxxon Pharma N : Download transcript	PU
2022	NOXXON Pharma N.V. has Changed its Name to TME Pharma N.V	CI
2022	Noxxon announces corporate action to start the parity period	AQ
2022	NOXXON Announces Updated Development Strategy Following Strong Clinical Benefit Observe..	CI
2022	Noxxon enters into collaboration with us national cancer institute to characterize effe..	AQ
2022	NOXXON Pharma N.V. Enters into Amaterial Transfer Agreement with the U.S. National Canc..	CI
2022	Noxxon Pharma N : KOL Event Presentation NOX-A12 Phase 1/2 GLORIA trial in glioblastoma	PU
2022	Noxxon presents full top-line results from nox-a12 phase 1/2 gloria trial in glioblasto..	AQ
2022	Noxxon to host key opinion leader webinar on gloria study top-line results of nox-a12 &..	AQ
2022	NOXXON announces convocation of the 2022 annual general meeting of shareholders	AQ
2022	NOXXON Announces Presentation of NOX-A12 Phase 1/2 Data in Glioblastoma at The 2022 ASC..	CI
2022	Noxxon amends equity-linked facility with atlas	AQ
2022	Noxxon Obtains Additional $1 Million in Remaining Tranches of Equity-linked Facility	MT
2022	Noxxon announces results of the extraordinary general meeting of shareholders	AQ
2022	Noxxon Pharma N.V. Announces Scientific Advisory Board Appointments	CI
2022	TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
2022	Noxxon announces eur2.375 million financing under agreement with atlas	AQ
2022	NOXXON Pharma N.V. Auditor Raises 'Going Concern' Doubt	CI
2022	Top-line results from noxxon's nox-a12 phase 1/2 gloria trial in brain cancer to be pre..	AQ
2022	Noxxon Pharma N : Top-line results from NOXXONs NOX-A12 Phase 1/2 GLORIA trial in brain ca..	PU
2022	Top-Line Results from NOXXON’S NOX-A12 Phase 1/2 GLORIA Trial in Brain Cancer to B..	CI
2022	NOXXON Announces Top-Line Data of Phase 1/2 GLORIA Study With NOX-A12 in Partially Rese..	CI
2022	Noxxon announces eur2.375 million financing under agreement with atlas	AQ
2022	Cancer-Focused Biotech Noxxon Secures Additional $2.7 Million Financing	MT
2022	Noxxon - half-yearly report on the liquidity contract with invest securities	AQ
2022	Noxxon provides progress update on the expansion arms of the phase 1/2 gloria trial wit..	AQ
2022	NOXXON Provides Progress Update on the Expansion Arms of the Phase 1/2 GLORIA Trial Wit..	CI
2022	Noxxon provides update on evaluation of nox-a12 in non- oncology indication by a leadin..	AQ
2022	NOXXON Pharma N.V. Provides Update on Evaluation of NOX-A12 in Non-Oncology Indication ..	CI
2022	NOXXON Pharma N.V. announced that it expects to receive €17 million in funding	CI
2021	Noxxon Gets Additional $19 Million Funding From Atlas Special Opportunities	MT
2021	Noxxon Pharma N : secures Euro 17 million expansion of equity-linked facility with Atlas t..	PU
2021	NOXXON Pharma N.V. Announces Appointment of Bryan Jennings as Additional Statutory Dire..	CI
2021	Noxxon Pharma N : announces results of the extraordinary general meeting of shareholders	PU
2021	Noxxon Pharma N : to participate in banking and investor conferences in January and Februa..	PU
2021	Global markets live: Intel, Tesla, Facebook, ABB, SGS...
2021	NOXXON Pharma N.V. Announces Enrolment of First Patient in the Expansion of the NOX-A12..	CI
2021	NOXXON Pharma N.V. Presents New Phase 1/2 Data On NOX-A12 & Radiotherapy Combination in..	CI
2021	Noxxon : New Phase 1/2 data on NOX-A12 & radiotherapy combination in brain cancer presente..	PU
2021	Noxxon Pharma N : Presentation by Dr. Frank Giordano at the Society for Neuro-Oncology (SN..	PU

1 2 3 4 5 Next

Upcoming event on TME PHARMA N.V.

04/26/23

FY 2022 Earnings Release (Projected)

Company calendar

Upcoming sector events

04/27/23	ALNYLAM PHARMACEUTICALS, INC. : Q1 2023 Earnings Release (Projected)
04/27/23	SEAGEN INC. : Q1 2023 Earnings Release (Projected)
05/03/23	IQVIA HOLDINGS INC. : Q1 2023 Earnings Release (Projected)
05/11/23	MODERNA, INC. : Q1 2023 Earnings Release (Projected)

More events

Sector

Healthcare
	Pharmaceuticals & Medical Research
		Biotechnology & Medical Research
			Biotechnology & Medical Research
				Other Biotechnology & Medical Research